Notes

59 Rosanoff A et al., “Essential nutrient interactions: does low or suboptimal magnesium status interact with vitamin D and/or calcium status?” Adv Nutr; vol. 7, no. 1, pp. 25-43, 2016.

60 Aikawa JK, Magnesium: Its Biologic Significance. CRC Press, Boca Raton, FL, 1981.

61 McArdle WD, Katch FI, Katch VL, Essentials of Exercise Physiology. 2nd ed Lippincott Williams & Wilkins, Philadelphia, 2000.

62 Levine BS, Coburn JW, “Magnesium, the mimic/antagonist of calcium.” N Engl J Med, vol. 310, pp. 1253-1255, 1984.

63 Iseri. LT, French JH, “Magnesium: nature’s physiologic calcium blocker.” Am Heart J, vol.108, pp. 188-193, 1984.

64 Seelig MS, “Cardiovascular reactions to stress intensified by magnesium deficit in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications: a review.” J Am Coll Nutr, vol. 13, no. 5, pp. 429-446, 1994.

65 Rodale JR, Magnesium: The Nutrient That Could Change Your Life. Rodale Press, Emmaus, PA, 1971. Full text available at www.mgwater.com/ rodtitle.shtml.

66 .Hartwig A, “Role of magnesium in genomic stability.” Mutat Research, vol. 18, no. 475 (1-2), pp. 113-121, 2001.

67 Yang L et al., “Critical role of magnesium ions in DNA polymerase beta’s closing and active site assembly, “J Am Chem Soc, vol. 126, no. 27, pp. 8441-8453, 2004.

68 Tao MH et al., “Associations of intakes of magnesium and calcium and survival among women with breast cancer: results from Western New York Exposures and Breast Cancer(WEB) Study. “Am J Cancer Res, vol. 6, no. 1, pp. 105-113, 2015.

69 Walker GM, “Biotechnological implications of the interactions between magnesium and calcium.” Magnes Res, vol. 12, no. 4, pp. 303-309, 1999.

70 Louvet L et al., “characterisation of calcium phosphate clystals on calcified human aortic vascular smooth muscle cells and potential role of magnesium.” PLoS One, vol. 10, no. I, p. e0115342, 2015.

71 Teo KK et al., “Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomized trials.” Brit Med J, vol. 303, pp. 1499-1503, 1991.

72 Eades M, Eades MD, The Protein Power Lifeplan. Warner Books, New York, 1999.

73 Feskanich D et al., “Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postn1enopausal women.” Am J Clin Nutr, vol. 77, no. 2, pp. 504-511, 2003.

74 Bolland MJ et al., “Vascular events in healtl1y older women receiving calcium supplementation: randomised controlled trial.” BMJ, vol. 336,p. 336, 2008.

75 Bolland MJ et al., “Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.” BMJ, vol. 341, 2010.

76 Bolland MJ et al., “Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative Lin1ited Access Dataset and Meta-Analysis.” BM], vol. 342, p. d2040, 2011.

77 Bolland MJ et al., “Calcium supplements and cardiovascular risk: 5 years on.” Ther Adv Drug Saf, vol. 4, no. 5, pp.199-210, 2013.

78 Bolland MJ et al., “Calcium intake and risk of fracture: systematic review.” BMJ, vol. 351, p. H4580, 2015.

79 Anderson JJB et al., “Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the Multi-Ethnic Study of Anterosclerosis (MESA).” JAMA, vol 5, no. 10.

80 Abraham GE, “The Calcium Controversy.” J Applied Nutr, vol. 34, no. 2, 1982.

81 Kakigi CLM et al., “Self-reported calcium supplementation and age-related macular degeneration.” JAMA Ophthalmol, vol. 133, no. 7, pp. 746-754, 2015.

82 Durlach J, “Recommended Dietary Amounts of magnesium: Mg RDA.” Mages Res, vol. 2, no. 3, pp. 195-203, 1989.

83 Grober U, Schmidt J, Kisters K, “Magnesium in prevention and therapy.” Nutrients, vol. 7, no. 9, pp. 8199-8226, 2015.

84 Abood A, Vestergaad P, “Increasing incidence of p1i.inary hyperparathyrnoidism in Denmark.” Dan Med J, vol. 60, no. 2, pp. A4567, 2013.

85 McCarthy JT, Kumar R, “Divalent cation metabolism: magnesium.” In Schrier R (series ed.), The Atlas of Diseases of the Kidney, Blackwell, Oxfordshire, 1999.

86 HeatonFW “Role of magnesium in enzyme systems,” in Siegel H (ed.), Metal Ions in Biologic Systems, Marcel Dekker, New York, 1990.

87 Abraham GE, Flechas JD, “Management of fibromyalgia: rationale for the use of magnesium and malic acid.” J Nutr Med, vol. 3, pp. 49-59, 1992.

88 Andrea Rosanoff, www.prohealth.com/library/print.cfin?libid=l4606.

89 de Baaij JHF et al, “Magnesium in man: implications for health and disease.” Physiol Rev, vol. 95, no. 1, pp. 1-46, 2015.

90 Shi J et al., “Mechanism of magnesium activation of calcium-activated potassium channels.” Nature, vol. 418, no. 6900, pp. 876-880, 2002.

91 Kant AK, “Consumption of energy-dense, nutrient-poor foods by adult An1ericans: nutritional and health in1plications. The third National Health and Nutrition Examination Survey,1988-1994.” Am J Clin Nutr, vol. 72, no. 4, pp. 929-936, 2000.

92 “Junk food makes up quarter of US diet.” NBC News, July 2004. http://tinyurl.com/ntr6aus.

93 Mmketplace, March 2013. http://tinyurl.com/ovjht7q.

94 Institute of Medicine, Dietary Reference Intake for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academy Press, Washington DC, 1997.

95 Sale K, “Lessons from the Luddites: setting limits on technology:” Nation, June 5, 1995.

96 Samsel A, Seneff S, “Glyphosate, pathways to modern diseases II: celiac sprue and gluten intolerance.” Interdisc Toxcol, vol. 6, no. 4, pp. 159-184, 2013.

97 http://soilandl1ealth.org/w-pcontent/uploads/01aglibrary/010l06voisin/010106gttoc.html.

98 www.mgwater.com/leaching.shtml.

99 www.sunarc.org/JAD97.pdf.

100 Grober U, Shchmidt J, Kisters K, “Magnesium in prevention and therapy. “Nutrients, vol. 7, no. 9, pp. 81-99-8226, 2015.

101 Institute of Medicine, Diatary Reference Intake for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academies Press, Washington DC, 1997.

102 https://ocls.od.nih.gov/factsheets/Magnesium-HealthProfessional/#h4.

103 Eades M, Eades MD, The Protein Power Lifeplan. Warner Books, New York, 1999.

104 Campbell-McBride N, Gut and Psychology Syndrome. Medinform, Carmbridge, UK, 2010

105 https:/ /www.youtube.com/watch?v=dBnniua6-oM.

106 Werbach MR, Nutritional Influences on Illness. Thorstons Publishing Group, Wellingborough, Northamptonshire, 1989.

107 Graham L, Caesar J, Burger A, “Gasutointestinal absorption and excretion of Mg.” Metabolism, vol. 9, 1960.

108 Disch G et al., “Interactions between magnesium and iron. In vitro studies.” Arzneimittel-Forschung, vol. 44, no. 5, pp. 647-650, 1994.

109 Dean CFA, Wheeler LC, JBS for Dummies. Wiley, Hoboken, NJ, 2005.

110 Crook W, Dean CFA, The Yeast Connection and Women’s Health. Square One, Garden City Park, NY, 2007.

111 Laires MJ et al., “Role of cellular magnesiru11 in healtl1 and human disease.” Front Biosci, vol. 9, pp. 262-276, 2004.

112 Eades M, Eades MD, The Protein Power Lifeplan. Warner Books, New York, 1999.

113 Freitag J, Hruska K, “Pathophysiology of Nephrolithiasis.” In The Kidney and Body Fluids in Health and Disease, ed. S. Klahr; p. 550. Springer, New York, 2013.

114 Linderman RD, “Influence of various nutrients and hormones on urinary divalent cation excretion. ” Ann NY Acad Sci, vol. 162, pp. 802-809, 1969.

115 Lemann J et al., “Evidence that glucose ingestion inhibits net renal tubular reabsorption of calcium and magnesium in man.” J Lab Clin Medicine, vol. 75, pp. 578-585, 1970.

116 Michiel RR, “Sudden death in a patient on a liquid protein diet.” New Engl J Med, vol. 298, pp. 1005-1007, 1978.

117 Werbach MR, “Nutritional influences on aggressive behavior.” J Orthomolec Medicine, vol. 7, no. 1, 1995

118 Boyle NB, Lawton CL, Dye L, “The effects of magi1esium supplementation on subjective anxiety.” Magnes Res 2016, Nov. 17.

119 Rogers SA, Depression Cured at Last. SK Publishing, Sarasota, FL, 2000.

120 Durlach J, “Diverse applications of magnesium therapy.” In Handbook of Metal=Ligand Interactions in Biological Fluids-Bioinorganic Medicine, vol. 2, Marcel Dekker, New York, 1995.

121 Mocci F, Canalis P, Tomasi PA, Casu F, Pettinato S, “The effect of noise on serum and urinary magnesium and catecholamines in humans.” Occup Med (Lond), vol. 51, no. 1, pp. 56-61, 200 l.

122 Penland JG, “Quantitative analysis of EEG effects followii1g experimental marginal magnesium and boron deprivation.” Magnes Res, vol. 8, no.4, pp. 341-358, 1995.

123 Seelig MS, “Mechanisms of interactions of stress, stress hormones and magnesium in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications: a review.” J Am Coll Nutr; vol. 13, no. 5, pp. 429-446, 1994.

124 Cernak I et al., “Alterations in magnesium and oxidative status during chronic emotional stress.” Magnes Res, vol. 13, pp. 29-36, 2000.

125 Classen HG et al., “Coping with acute stress reaction by plentiful oral magnesium supply.” Magnes Bull, vol. 17, pp. 1-8, 1995.

126 Sartori SB et al., “Magnesium deficiency ii1duces anxiety and HPA axis dysregulation: Modulation by therapeutic drugtreatment. “Neuropharmacology, vol. 62, no. 1, pp. 304-312, 2012.

127 Klerman GL, Weissman MM, “Increasing rates of depression.” JAMA, vol. 261, no. 15, pp. 2229-2235, 1992.

128 WeissmanMM, “Cross-national epidemiology of major depression and bipolar disorder.” JAMA, vol. 276, no. 4, pp. 293-299, 1996.

129 Murphy JM, “A 40-year perspective on the prevalence of depression: the Stirling County Study.” Arch Gen Psychiatry, vol. 57, no. 3, pp.-209-215, 2000.

130 Cox RH, Shealy CN, Cady RK, Veehoff D, Burnetti Awell M, Houston ‘”Significant magnesium deficiency in depression.” J Neurol Orthop Med S111g, vol. 17, pp. 7-9, 1996.

131 Teymoor Y et al., “Dietary magnesium intake and the incidence of depression: a 20-year follow-up study. “J Affect Disord, vol. 193, pp. 94-98, 2016.

132 Jacka FN, Overland S, Stewart R, Tell GS, Bjelland I, Mykletun A, “Association between magnesium intake and depression and anxiety in Community-dwelling adults: the Hordaland Health Study.” Aust NZJ Psychiatry, vol. 43, no. 1, pp. 45-52, 2009.

133 Kaur J et al., “Role of dietary factors in psychiatry.” Delhi Psychiatry, vol. 17, no. 2, pp. 452-457, 2014.

134 Gottesmann C, “GABA mechanisms and sleep.” Neuroscience vol. 111 no. 2, pp. 231-239, 2002.

135 Moykkynen T et al., “Magnesium potentiation of the function of native and recombinant GABA(A) receptors.” Neuroreport. July 20, 2001, vol. 12, no. 10, pp. 2175-2179.

136 Poleszak E et al., “Benzodiazepine/GABA(A) receptors are involved in magnesium-induced anxiolytic-like behavior in mice.” Pharmacol Rep, vol. 60, no.4, pp.483-489,2008.

137 Held K et al., “Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans.” Pharmacopsychiatry, vol. 35, no. 4, pp. 135-143, 2002.

138 Nielsen FH, Johnson LK, Zeng H, “Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years, with poor quality sleep.” Magnes Res, vol. 23, no. 4, pp. 158-168, 2010.

139 Omiya K et al., “Heart-rate response to sympathetic nervous stimulation, exercise, and magnesium concentration in various sleep conditions. “Int J Sport Nutr Exerc Metab, vol. 19, no. 2, pp. 127-135, 2009.

140 Takase B et al., “Effects of chronic sleep deprivation on autonomic activity by examining heart rate variability, plasma catecholamine, and intracellular magnesium levels.” Biomed Pharmacother, vol. 58, suppl. 1, pp. S35-S39, 2004.

141 Takase B et al., “Effect of chronic stress and sleep deprivation on both flow-mediated dilation in the brachial artery， catecholamine, and intracellular magnesium levels.” Biomed Pharmacother, vol. 58, suppl. 1, pp. S35-S39, 2004. and the intracellular magnesium level in humans.” Clin Cardiol, vol. 27, no. 4, pp. 223-227, 2004.

142 Billyard AJ et al., “Dietary magnesium deficiency decreases plasma melatonin in rats.” Magnes Research, vol. 19, no. 3, pp. 157-161, 2006.

143 “Nearly 7 in 10 Americans are on prescription drugs.” Science News, June 19, 2013.

144 Pigeon WR, Yurcheshen M, “Behavioral sleep medicine interventions for restless legs syndrome and periodic limb movement disorder.” Sleep Medicine Clinics, vol. 4, no. 4, pp. 487-494, 2009.

145 Hornyak Met al., “Magnesium therapy for periodic leg movements- related insomnia and restless legs syndrome: an open pilot study.” Sleep, vol. 21, no. 5, pp. 501-505, 1998.

146 Bartell S, Zallek S, “Intravenous magnesium sulfate may relieve restless Legs syndrome in pregnancy.” J Clin Sleep Med, vol. 2, no. 2, pp. 187-188, 2006.

147 Aurora RN et al, “The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an An1erican Academy of Sleep Medicine Clinical Practice Guideline.” Sleep, vol. 35, no. 8, pp. 1039-1062, 2012.

148 Rogers SA, Depression Cured at Last. SK Publishing, Sarasota, FL, 2000.

149 Starobrat-Hermelin B, Kozielec T, “The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test.” Magnes Res, vol. 10, no. 2, pp. 149-156, 1997.

150 Olfman, S. No Child Left Different. Praege1; Westport, CT, 2006, p. I.

151 Galland L, Buchman D, Superimmunity for Kids. Dell, New York, 1988.

152 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Sante Fe, NM, 1997.

153 Weaver K, “Magnesium and migraine.” Headache, vol. 30, p. 168, 1990.

154 Mauskop A, Fox B, What Your Doctor May Not Tell You About Migraines. Warner Books, New York, 2001.

155 Mauskop A et al., “Deficiency in serum ionized magnesium but not total magnesium in patients with migraines. Possible role of ICa2/IMg2 ratio.” Headache, vol. 33, no. 3, pp. 135-138, 1993.

156 Mauskop A et al., “Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magi1esium levels: a pilot study.” Clin Sci (Colch), vol. 89, no. 6, pp. 633-636, 1995.

157 Mauskop A, Altura BT, et al., “Intravenous magnesium sulfate rapidly alleviates headaches of various types.” Headache, vol. 36, no. 3, pp.15-160, 1996.

158 Mauskop A, Altura BM, “Role of magnesium in the pathogenesis and treatment of migraines.” Clin Neurosci, vol. 83, no. 5, pp. 2←27, 1998.

159 Peikert A, Wilin1zig C, et al., “Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study.” Cephalalgia, vol. 16, no. 4, pp. 257-263, 1996.

160 Mauskop A, “Why all migraine patients should be treated with magnesium.” J Neural Transm, vol. 119, pp. 575-579,2012.

161 Chiu HY et al., “Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials.” Pain Physician, vol. 19, no. 1, pp. E97-Ell2, 2016.

162 Assarzadegan F et al., “Serum concentration of magnesium as an independent risk factor in migraine attacks: a matched case-control study and review of the literature.” Int Clin Psychopharmacol, vol. 31, no. 5, pp. 287-292, 2016.

163 Mauskop A, Fox B, What Your Doctor May Not Tell You About Migraines. Warner Books, New York, 2001.

164 Shaik MM, Gan SH, “Vitamin supplementation as possible prophylactic treatment against migraine with aura and menstrual migraine,” BioMed Research International, vol. 2015, article ID 469529, 2015.

165 Buse DC et al., “Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study.” Headache, 52, no. 10, pp. 1456-1470, 2012.

166 Mauskop A et al., “Intravenous magnesium sulfate relieves cluster headaches in patients, with low serum ionized magnesium levels.” Headache, vol. 35, no. 10, pp. 597-600, I 995.

167 Mauskop A, Altura BT et al., “Intravenous magnesium sulfate rapidly alleviare:5 headaches of various types.” Headache, vol. 36, no. 3, pp. 154-160, 1996.

168 Crosby V, Wilcock A, Corcoran R, “The safety and efficacy of a single dose (500mg or 1g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. ” J Pain Symptom Management, vol. 20, no. 1, pp. 35-39, 2000.

169 Meucci RD, Fassa AG, Faria NMX, “Prevalence of chronic low back pain: systematic review.” Revista de Saùde Pùblica, vol. 49, no. 1, p. 1, 2015.

170 Yousef AA, Al-Deeb AE, “A double-blinded randomized controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component.”Anaesthesia, vol. 68, no. 3, pp. 260-266, 2013.

171 SarnoJ. Healing Back Pain. Grand Central Publishing, New York, 2001

172 www.ninds.nih.gov/ disorders/tourette/ detail_tourette.htm.

173 Grimaldi BL, “The central role of magnesium deficiency in Tourette’s syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette’s syndrome and several reported comorbid conditions.” Med Hypotheses, vol. 58, no. 1, pp.47-60, 2002

174 Nielsen FH, Lukaski HC, “Update on the relationship between magnesium and exercise. “Magnes Res, vol. 19, no. 3, pp. 180-189, 2006.

175 Seelig MS, “Athletic stress, performance and magnesium in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications: a review.” J Am Coll Nutr, vol. 13, no. 5, pp. 429-446, 1994.

176 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Santa Fe, NM, 1997.

177 Seelig MS, “Athletic stress, performance and magnesium in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic Implications: a review.” J Am Coll Nutr, vol. 13, no. 5, pp.429-4-46, 1994.

178 Singh RB, ‘Effect of dietary magnesium supplementation in the prevention of coronary heart disease and sudden cardiac death.” Magnesium Trace Elem, vol. 9, pp. 143-151, 1990.

179 Stendig-Lindberg G, “Sudden death of athletes: is it due to long-term changes in serum magnesium, lipids and blood sugar?” J Basic Clin Physiol Pharmacol, vol. 3, no. 2, pp. 153-164, 1992.

180 Institute of Medicine, Dietary Reference Intake for Calcium, Phosphorus, Magnesium. Vitamin D, and Fluoride. National Academy Press, Washington DC, 1997.

181 Durlach J et al., “Physiopathology of symptomatic and latent forms of central nervous hyperexcitability clue to magnesium deficiency: a current general scheme.” Magnes Res, vol. 13, no. 4, pp. 293-302, 2000.

182 www.aclelaicle.edu.au/ press/ titles/ magnesium.

183 Cernak I et al., “Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans.” J Neurotrauma, vol. 17, no. 1, pp. 53-68, 2000.

184 Memon ZI et al., “Predictive value of serum ionized but not total magnesium levels in head injuries.” Scand J Clin Lab Invest, vol. 55, no. 8, pp. 671-677, 1995.

185 Heath DL, Vink R, “Brain free magnesium concentration is predictive of motor outcome following traumatic axonal brain injury in rats.” Magnes Res, vol. 12, no. 4, pp. 269-277, 1999.

186 Blaylock RL, Excitotoxins The Taste That Kills. Health Press, Sante Fe, NM, 1997.

187 Marcus JC et al., “Serum ionized magnesium m post-traumatic headaches.” J Pediatr, vol. 139, no. 3, pp. 459-462, 2001.

188 Personal correspondence with Dr. Russell Blaylock.

189 Altura BM, Altura BT, “Association of alcohol in brain injury，headaches, and stroke with brain-tissue and serun 1 levels of ionized magnesium: a review of recent fu1dings and mechanisms of action.” Alcohol, vol. 19, no. 2, pp. 119-130, 1999.

190 Altura BM et al., “Alcohol-induced spasms of cerebral blood vessels: relation to cerebrovascular accidents and sudden death.” Science, vol. 220, 110. 4594, pp. 331-333, 1983.

191 Zhang A et al., “Chronic treatment of cultured cerebral vascular smooth cells with low concentration of ethanol elevates intracellular calcium and potentiates prostanoid-induced rises in [Ca2+]i: relation to etiology of alcohol-induced stroke.” Alcohol, vol. 14, no. 4, pp. 367-371, 1997.

192 Altura BM, Altura BT, “Association of alcohol in brain injury, headaches, and stroke with brain-tissue and serum levels of ionized magnesium: a review of recent findiI1gs and mechanisms of action.” Alcohol, vol. 19, no. 2, pp. 119-130, 1999.

193 Abbot L et al., “Magnesium deficiency in alcoholism: possible contribution to osteoporosis and cardiovascular disease in alcoholics.” Alcohol Clin Exp Res, vol. 19, pp. 1076-1082, 1994.

194 Altura BM, Altura BT, “Association of alcohol in brain ii1jury, headaches, and stroke with brain-tissue and serum levels of ionized magnesium: a review of recent findings and mechanisms of action.” Alcohol, vol. 19, no. 2, pp. 119-130, 1999.

195 Altura BM et al., “Extracellular magnesium regulates nuclear and perinuclear free ionized calcium in cerebral vascular smooth muscle cells: possible relation to alcohol and central nervous system injury.” Alcohol, vol. 23, no. 2, pp. 83-90, 2001.

196 Ema M et al., “Alcohol-induced vascular damage of braii1is ameliorated by administration of magnesium.” Alcohol, vol. 15, no. 2, pp. 95-103, 1998.

197 www.cdc.gov/stroke/facts.htm.

198 Yang CY, “Calcium and magnesium in drinking water and risk of death from cerebrovascular disease.” Stroke, vol. 18, no. 8, pp.411–414, 1998.

199 Bain LK et al., “The relationship between dietary magnesium intake, stroke and its major risk factors, blood pressure and cholesterol, in tl1e EPIC-Norfolk cohort.” Int J Cardiol, vol. l 96, pp. 108-114, 2015.

200 Altura BT, Altura BM, “Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries.” Neurosci Lett, vol. 20, no. 3, pp. 323-327, 1980.

201 Altura BT, Altura BM, “Interactions of Mg and Kon cerebral vessels-aspects in view of stroke. Review of present status and new findings.” Magnesium, vol. 3, nos. 4-6, pp. 195-211, 1984.

202 LiV et al., “Antioxidants prevent elevation in [Ca(2+)](i) induced by low extracellular magnesium in cultured canine cerebral vascular smooth muscle cells: possible relationship to Mg(2+) deficiency-induced vasospasm and stroke.” Brain Res Bull, vol. 52, no. 2, pp. 151-154, 2000.

203 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Sante Fe, NM, 1997, p.181.

204 Altura BT et al., “Low levels of serum ionized magnesium are found in patients early after stroke which result in rapid elevation in cytosolic free calcium and spasm in cerebral vascular muscle cells.” Neurosci Lett, vol. 230, no. l, pp.37-40, 1997.

205 Altura BM, Altura BT, “Association of alcohol in brain injury, headaches, and stroke with brain-tissue and serum levels of ionized magnesium: a review of recent findii1gs and mechanisms of action.” Alcohol, vol.19, no. 2, pp.119-130, 1999.

206 Li Wet al., “Antioxidants prevent depletion of [Mg2+]i induced by alcohol in cultured canine cerebral vascular smooth muscle cells: possible relationship to alcohol-induced stroke.” Brain Res Bull, vol. 55, no. 4, pp.475–478, 2001.

207 Haley D, Politics in Healing BioMed Publishing Group, 2000.

208 http：//tinyurl.com/hy2qg87.

209 Horn B, “Magnesium and the cardiovascular system.” Magnesium, vol. 6, pp. 109-111, 1987.

210 Schulz-Stubner S et al., “Magnesium as part of balanced general anaesthesia with propofol, remifentanil and mivacurium: a double-blind, randomized prospective study in 50 patients.” Eur J Anaesthesiol, vol. 18, 110. 11, pp. 723-729, 2001.

211 www.mgwater.com/rodtitle.shtml.

212 Yuen AW, Sander JW, “Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis.” Epilepsy Res, vol. l00, nos. 1-2, pp. 152-156, 2012.

213 Pall M, “Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects.” J Cell Mol Med, vol. 17, no. 8, pp. 958-965, 2013.

214 Goldberg B, Heart Disease. Future Medicine Publishing, Tiburon, CA, 1998.

215 Altura BT et al., “Magnesium dieta1y intake modulates blood lipid levels and artherogenesis. ” Proc Natl Acad Sci, vol. 87, no. 5, pp. 1840-1844, 1990.

216 Singh RB et al., “Does dietary magnesium modulate blood lipids?” Biol Trace Elem Res, vol. 30, pp. 50-64, 1991.

217 Corica Fetal., “Effects of oral magnesium supplementation on plasma lipid concentrations m patients with non-insulin dependent diabetes mellitus.” Magnes Res, vol. 7, pp. 43-46, 1994.

218 Durlach J, “Commentary on recent epidemiological and clinical advances.” Magnes Res, vol. 9, no. 2, pp. 139-141, 1996.

219 Fallon S, Enig M, Nourishing Traditions. Locomotion Press, Baltm1ore, MD, 1995.

220 Gao Met al., “Cardiovascular risk factors emerging in Chii1ese populations undergoing urbanization.” Hypetens Res, vol. 22, pp. 209-215, 1999.

221 Marier JR, “Magnesium content of the food supply ii1 the modern-day world.” Magnesium, vol. 5, pp. 1-8, 1986.

222 Liu Let al., “Comparative studies of diet-related factors and blood pressure among Chinese and Japanese: results from the China-Japan Cooperative Research of tl1e WHO-CARDIAC Study. Cardiovascular disease and alimentaly comparison. ” Hypertens Res, vol. 23, pp. 413-420, 2000.

223 Friedlang GW, Friedman M, Medicine’s10 Greatest Discoveries. Yale University Press, New Haven, CT,1998.

224 Ford R, Stale Food vs. Fresh Food: The Cause and Cure of Choked A1te1ies and Related Problems. Magnolia Laboratories, Pascagoula, MS, 1969

225 Erasmus U, Fats That Heal, Fats That Kill. Alive Books, Burnaby, BC, 1993, p. 64.

226 Swenson AM et al., “Magnesium modulates actin binding and ADP release in myosin motors.” J Biol Chem, vol. 289, no. 34, pp.-23977-23991, 2014.

227 Rosanoff A, Seelig MS, “Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals.” J Am Coll Nutr, vol. 23, no. 5, pp. 501S-505S, 2004.

228 Seelig M, Rosanoff A, The Magnesium Facto. Avery, New York, 2003, p. 244.

229 McCully KS, “Homocysteine, folate, vitamin B6, and cardiovascular disease.” JAMA, vol. 279, no. 5, pp. 392-393, 1998.

230 McCully KS, “Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.” Am J Pathol, vol. 56, no. I, pp. 111- 128, 1969.

231 Eikelboon JW et al., “Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.” Ann Intern1Wed, vol. 131, no.5, pp. 363-375, 1999.

232 Boushey CJ et al., “A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of i11creasmg folic acid intakes.” JAMA, vol. 274, no. 13, pp. 1049-1057, 1995.

233 Confalonieri M et al., “Heterozygosity for homocysteinuria: a detectable and reversible lisk factor for pulmona1- ythromboembolism.” A1onaldi Arch Chest Disease, vol. 50, no. 2, pp. 114-115, 1995.

234 Altura B, Altura B, “Magnesium: the forgotten mineral m cardiovascular health and disease.” A Gem Lecture at SUNY Downstate. Alumni Today, pp. 11-22, spring 2001.

235 Li Wet al., “Extracellular magnesium regulates effects of vitamin B6, Bl2 and folate on homocysteinemia-induced depletion of intracellular free magnesium ions in canine cerebral vascular smooth muscle cells: possible relationship to [Ca2+]i, atherogenesis and stroke.” Neurosci Lett, vol. 274,110. 2, pp. 83-86, 1999.

236 Shamsuddin AM, “Inositol phosphates have novel anti-cancer function.” J Nutr, vol. 125 (suppl.), pp. 725S-732S, 1995.

237 Rowley KG et al., “Improvements in circulating cholesterol, antioxidants, and homocysteine after dietary intervention in an Australian Aboriginal community.” Am J Clin Nutr, vol. 74, no. 4, pp. 442-448, 2001.

238 Tice JA et al., “Cost-effectiveness of vitami11 therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond.” JAMA, vol. 286, no. 8, pp. 936-943, 2001.

239 Vollset SE et al., “Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordal and Homocysteine Study.” Am J Clin Nutr, vol. 74, no. 1, pp. 130-136, 2001.

240 Batmanghelidj F, Your Body’s Many Cries for Water. Global Health Solutions, Falls Church, VA, 1997.

241 Altura BM et al., “Hypomagnesemia and vasoconstriction: possible relationship to etiology of sudden death ischemic heart disease and hypertensive vascular diseases.” Artery, vol. 9, no. 3, pp. 212-231, 1981.

242 Mindell E, Prescription Alternatives. Keats Publishing, Los Angeles, I999.

243 Pierce JB, Heart Healthy Magnesium: Your Nutritional Key to Cardiovascular Wellness. Avery, New York, 1994.

244 Kisters K et al., “Hypomagnesaemia, borderline hypertension and hyperlipidaemia. ”Magnesium Bull, vol. 21, pp. 31-34, 1999.

245 Altura BM, Altura BT et al., “Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ.” Science, vol. 223, no. 4642, pp. 1315-1317, 1984.

246 Resnick LM et al., “Factors affecting blood pressure responses to diet: the Vanguard study.” Am J Hypertens, vol. 13, no. 9, pp. 956-965, 2000.

247 Altura BM, Altura BT, “Interactions of Mg and K blood vessels-aspects in view of hypertension. Review of present status and new findings. ” Magnesium, vol. 3, nos. 4-6, pp. 175-194, 1984.

248 Lukaski HC, Nielsen FH. “Dietary magnesium depletion affects metabolic responses during submaximal exercise in postmenopausal women.” J Nutl; vol. 132, no. 5, pp. 930-935, 2002.

249 Goldberg B, Heart Disease. Future Medicine Publishing, Tiburon, CA, 1998.

250 Sei Met al., “Nutritional epidemiological study on mineral intake and mortality from cardiovascular disease.” Tokushima J Exp Med, vol. 40, nos. 3-4, pp.199-207, 1993.

251 Zwillinger L, “Effect of magnesium on the heart.” Klin Wochenschr, vol. 14, pp. 1429-1433, 1935.

252 MMWR, vol. 48, no. 30, pp. 649-656, 1999

253 Mehta LS, Beckie TM, DeVon HA, et al., “Acute myocardial n1farction m women: A scientific statement from the America Heart Association.” Circulation, vol. 134, no. 20, 2016.

254 Rademaker M, “Do women have more adverse drug reactions?” Am J Clin Dermatol, vol. 2, no. 6, pp. 349-351, 2001.

255 Seelig M, Rosanoff A, The Magnesium Factor. Avery, New York, 2003, p. 244.

256 Singh RB, “Magnesium status and risk of coronary artery disease in rural and urban populations with valiable magnesium consumption.” Magnes Res, vol. 10, no. 3, pp. 205-213, 1997.

257 Liao F, Folsom AR, “Is low magnesium concentration a risk factor for coronary heart disease? The atherosclerosis risk in communities (ARIC) study.” Am Heart J, vol. 136, no. 3, pp. 480-490, 1998.

258 Ford ES, “Serum magnesium and ischemic heart disease: findings from a national of US adults.” Int J Epidemiol, vol.28, pp. 645-651,

259 Seelig MS, Heggtveit HA, “Magnesium interrelationships in ischemic heart disease: a review.” Am J Clin Nutr, Vol. 27, no. 1, pp.59–79, 1974.

260 Sherer Y, Bitzur R, Cohen H, Shaish A, Varon D, Shoenfeld Y, Harats D, “Mechanisms of action of the anti- atherogenic effect of magnesium: lessons from a mouse model.” Magnes Res, vol. 14, no. 3, pp. 173-179, 2001.

261 Morrill GA, Gupta RK, Kostellow AB, Ma GY, Zhang A, Altura BT, Altura BM, “Mg2 modulates membrane sphingolipid and lipid seco d messenger levels in vascular smooth muscle cells.” FEBS Lett, vol. 440, nos. l-2, pp.167-171, 1998.

262 Yang ZW, Gebrewold A, et al., “Mg++-induced endothelial-dependent relaxation of blood vessels and blood pressure lowering: role of NO.” Am J Plrysiol Regul Integr Comp Physiol, vol. 278, pp. R628-639, 2000.

263 Kang DH, Park SK, Lee IK, Johnson RJ, “Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells.” J Am Soc Nephrol, vol. 16, no. 12, pp. 3553-3562, 2005.

264 Shrivastava AK et al., “C-reactive protein, inflammation and coronary heart disease.” Egyptian Heart J, vol. 67, no. 2, pp. 89-97, 2015.

265 Qu X et al., “Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies.” PloS One, vol. 8, no. 3, p. e57720, 2013.

266 Dibaba DT et al., “Dieta1y magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review.” Eur J Clin Nutr; vol. 68, no. 4, pp. 510-516, 2014.

267 King DE, Mainous AG, Geesey ME, Egan BM, Rehman S, “Magnesium supplement intake and C-reactive protein levels in adults.” Nutr Res, vol. 26, pp. 193-196, 2006.

268 Pierce JB, Heart Healthy Magnesium: Your Nutritional Key to Cardiovascular Wellness. Avery, New York, 1994.

269 Shechter M et al., “Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.” Magnes Res, vol. 13, no. 4, pp. 275-284, 2000.

270 Zwillinger L, “Effect of magnesium on the heart.” Klin Wochenschr, vol. 14, pp. 1429-1433, 1935.

271 Boyd LJ et al., “Magnesium sulfate in paroxysmal tachycardia.” Am J Med Sci, vol. 206, pp. 43–48, 1943.

272 Teo KK et al., “Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomized trials.” Brit Med J, vol. 303, pp. 1499-1503, 1991.

273 Teo KK, Yusuf S, “Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence.” Drugs, vol. 46, pp. 347-359, 1993.

274 Woods KL et al., “Intravenous magnesium sulfate in suspected acute myocardial infarction: results of tl1e second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2).” Lancet, vol. 339, pp. 1553-1558, 1992.

275 Woods KL, Fletcher S, “Long-term outcome after intravenous magnesium sulphate m suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2).” Lancet, vol. 343, pp. 816-819, 1994.

276 Ravn HB, “Pharmacological effects of magnesium on arterial thrombosis-mechanisms of action?” Magnes Res, vol. 12, no. 3, pp. 191- 199, 1999.

277 Young IS et al., “Magnesium status and digoxin toxicity.” Br J Clin Phrmacol, vol. 32, no. 6, pp. 717-721, 1991.

278 Lewis R et al., “Magnesium deficiency may be an important determinant of ventricular ectopy in digitalised patients with chronic atrial fibrillation.” Br J Clin Pharmacol, vol. 31, no. 2, pp. 200-203, 1991.

279 ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group, “ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.” Lancet, vol. 345, pp. 669-685, 1995.

280 Seelig MS, “Cardiovascular reactions to stress intensified by magnesium deficit in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications: a review.” J Am Coll Nutr. vol. 13, no. 5, pp. 429-446, 1994.

281 Woods KL, Fletcher S, “Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2).” Lancet, vol. 343, pp. 816-819, 1994.

282 Shechter M, Shechter A, “Magnesium and myocardial infarction.” Clin Calcium, vol. 15, no. 11, pp. I 11-115, 2005.

283 Shechter M, Bairey Merz CN, Stuelilinger HG, Slany J, Pachmger O, Rabmowitz B, “Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease.” Am J Cardiol, vol. 91, no. 5, pp. 517-521, 2003.

284 Shechter M, “Does magnesium have a role in the treatment of patients with coronary artery disease?” Am J Cardiovasc Drugs, vol. 3, no. 4, pp. 231-239, 2003.

285 Shechter M, Hod H, Rabinowitz B, Boyko V, Chouraqui P, “Long-term outcome of intravenous magnesium therapy in thrombolysis-ineligible acute myocardial infarction patients.” Cardiolgy; vol. 99, no. 4, pp. 205- 210, 2003.

286 Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN, “Oral magnesium therapy improves endothelial function in patients with coronary artery disease.” Circulation, vol. 102, no. 19, pp. 2353-2358, 2000.

287 Shechter M, Merz CN, Rude RK, Paul Labrador MJ, Meisel SR, Shah PK, Kaul S, “Low intracellular magnesium levels promote platelet- dependent thrombosis in patients with coronary artery disease.” Am Heart J, vol. 140, no. 2, pp. 212-218, 2000.

288 Reffelmann T et al., “Low serum magnesium concentrations predict increase in left ventricular mass over 5 years independently of common cardiovascular risk factors.” Atherosclerosis, vol. 213, no. 2, pp. 563-569, 2010.

289 Shechter M et al., “Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy.” Am J Cardiology, vol. 75, pp. 321-323, 1995.

290 Pierce JB, Heart Healthy Magnesium: Your Nutritional Key to Cardiovascular Wellness. Avery, New York. 1994.

291 Iseri LT, “Magnesium and cardiac arrhythmias.” Magnesium, vol. 5, nos. 3-4, pp. 111-126, 1986.

292 Iseri LT, Allen BJ, “Magnesium therapy of cardiac arrhythmias in critical-care medicine.” Magnesium, vol. 8, pp. 299-306, 1989.

293 Fox C et al., “Magnesium: its proven and potential clinical significance. South Med J, vol. 94, no. l2, pp. 1195-1201, 2001.

294 Perticone F et al., “Antiarrhythmic short-term protective magnesium treatment in ischemic dilated cardiomyopathy.” J Am Coll Nutr, vol.5, no. 3, pp. 492-499, 1990.

295 Durlach J et al., “Magnesium and ageing. II. Clinical data: aetiological mechanisms and pathophysiological consequences of magnesium deficit in the elderly.” Magnes Res, vol. 6, no. 4, pp. 379-394, 1993.

296 Pierce JB, Heart Healthy Magnesium: Your Nutritional Key to Cardiovascular Wellness. Avery, New York, 1994.

297 Adameova A.et al., “Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease.” Can J Physiol Pharmacol, vol. 87, no. 7, pp. 493-514, 2009.

298 Boyd LJ et al., “Magnesium sulfate in paroxysmal tachycardia.” Am J Med Sci, vol. 206, pp. 43-48, 1943.

299 Parikka HJ, Toivonen LK, “Acute effects of intravenous magnesium on ventricular refractoriness and monophasic action potential duration in humans.” Scand Cmdiovasc J, vol. 33, no. 5, pp. 300-305, 1999.

300 Thiele R, Protze F, Winnefeld K, Pfeifer R, Pleissner J, Gassel M, “Effect of intravenous magnesium on ventricular tachyarrhythmias associated with acute myocardial infarction.” Magnes Res, vol. 13, no. 2, PP. 111-112, 2000.

301 Ceremuzynski L et al., “Hypomagnesaemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation.” J Inter Med, vol. 247, pp. 78-86, 2000.

302 Dyckner T et al., “Magnesium deficiency in congestive heart failure.” Acta Pharmacol Toxicol Copenh, vol. 54, suppl. 1, pp. 119-123, 1984.

303 England MR et al., “Magnesium administration and dysrhythmias after cardiac surgery. “JAMA, vol. 268, pp. 2395-2402, 1992.

304 Caspi J et al., “Effects of magnesium on myocardial function after coronary artery bypass grafting.” Ann Thorac Surg, vol. 59, pp. 942-947, 1995.

305 Toraman F, Karabulut EH, Alhan HC, Dagdelen S, Tarcan S, “Magnesium infusion dramatically decreases the incidence of atrial fibrillation after coronary artery bypass grafting.” Ann Thorac Surg, vol. 72, no. 4, pp. 1256-1261, 2001.

306 Onalan O et al., “Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation.” Am J Cardiol, vol. 99, no. 12, pp.1726-1732,2007.

307 Khan AM, Lubitz SA, Sullivan LM et al., “Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study.” Circulation, vol. 127, no. 1, pp. 33-38, 2013.

308 www.rnareset.corn.

309 Patel NJ et al., “Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010.” Circulation, vol. 129, pp. 2371-2379, 2014.

310 Colilla S et al., “Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.” Am J Cardiol, vol. 112, no. 8, pp. 1142-1147, 2013.

311 www.naturalnews.com/04851l_MSG_magnesium_grutamates.html.

312 http://tinyurl.com/p8lhshk.

313 www.naturalnews.com/032084_sleep_apnea_epidernic.html.

314 O’Neal WT et al., “Coronary artery calcium progression and atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis.” Circ Cardiovasc Imaging, vol. 8, no. 12, 2015.

315 www.medscape.com/viewarticle/856658.

316 Shanahan CM, “Inflammation ushers in calcification: a cycle of damage and protection?” Circulation, vol. 116, pp. 2782-2785, 2007.

317 McEvoy JW et al., “Coronary artery calcium progression: an important clinical measurement? A review of published reports.” J Am Coll Cardiol, vol..56, no. 20, 2010.

318 Puri R et al., “Impact of statins on serial coronary calcification during atheroma progression and regression.” J Am Coll Cardiol, vol. 65, no. 13, pp. 1273-82, 2015, doi: 330.1016/jjacc.2015.01.036.

319 Lee SY et al., “Low serum magnesium is associated with coronary artery calcification in a Korean population at low risk for cardiovascular disease.” Nutr Metab Cardiovasc Dis, vol. 25, no. 11, pp. 1056-1061, 2015.

320 Hruby A et al., “Magnesium intake is inversely associated, with coronary artery calcification: the Framingham Heart Study.” JACC Cardiovasc Imaging, vol. 7, no. 1, pp. 59-69, 2014.

321 Handy CE et al, “The association of coronary artery calcium with noncardiovascular disease: the Multi-Ethnic Study of Atherosclerosis.” JACC Cardiovasc Imaging, vol. 9, no. 5, pp. 568-576, 2016.

322 Chun S, Choi Y, Chang Y, et al., “Sugar-sweetened carbonated beverage consumption and coronary artery calcification masymptomatic men and women.” Am Heart J, vol. 177, pp. 17-24, 2016.

323 www.msgtruth.org.

324 Seelig MS, “Review and hypothesis: might patients with the chronic fatigue syndrome have latent tetany of magnesium deficiency.” J Chron Fatigue Syndr, vol. 4, pp. 77-108, 1998.

325 Lichodziejewsa B et al., “Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation.” Amer J Cardiol, vol. 79, pp. 768-772, 1997.

326 Dritsa V et al., “Investigating tl1e mechanism of aortic valve stenosis: the role of magnesium salts.” J Cardiothorac Surg, vol. 8, suppl. 1, p. 018, 2013.

327 Bastard JP et al., “Recent advances m tl1e relationship between obesity, inflammation, and insulin resistance.” Eur Cytokine New, vol. 17, no.1, March 2006, 4-12.

328 Moslehi N et al., “Effects of oral magnesium supplementation on inflammatory markers in middle-aged overweight women.” J Res Med Sci, vol.17,no. 7,pp.607-614,2012.

329 Cassidy A et al, “Plasma adiponectin concentrations are associated with body composition and plant-based dietary factors in female twins.” J Nutr, vol. 139, no. 2, pp. 353-358, 2009.

330 Martinez JA·et al, “Epigenetics in adipose tissue, obesity, weight loss, and diabetes.” Adv Nutr, vol. 5, pp. 71-81, 2014.

331 Chacko SA et al., “Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals.” Am J Clin Nutr; vol. 93, no. 2, pp.463-473, 2011.

332 Seelig M, Rosanoff A, The Magnesium Factor. Avery, New York, 2003.

333 Nielsen FH, “Magnesium, inflammation and obesity in chronic disease.”Nutr Rev, vol. 68, no. 6, pp. 333-340, 2010.

334 Singh RB, “Association of low plasma concentrations of antioxidant vitamins, magnesium and zinc with high body fat per cent in Indian men. “Magnes Res, vol. 11, no. 1, pp.3-10, 1998.

335 Ma J et al, “Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness, the ARIC study, Artherosclerosis Risk in Communities Study.” J Clin Epidemiol, vol. 48, pp. 927-940, 1995.

336 Humphries Set al., “Low dietary magnesium is associated with insulin resistance in a sample of young, non-diabetic black Americans.” Am J Hypertens, vol. 12, no. 8, pt. 1, pp. 747-756, 1999.

337 Alzaid AA et al., “Effects of insulin on plasma magnesium in non- insulin-dependent diabetes mellitus: evidence for insulin resistance.” J Clin Endocrinol Metab, vol. 80, no. 4, pp. 1376-1381, 1995.

338 Barbagallo M et al., “Altered cellular Magnesium responsiveness to hyperglycemia in hypertensive subjects.” Hypertension: vol. 38, no. 3, pt. 2, pp. 612-615, 2001.

339 Dominguez LJ et al., “Magnesium responsiveness to insulin and insulin-like growth factor I in erythrocytes from normotensive and hypertensive subjects.” J Clin Endocrinol Metab, vol. 83, no. 12, pp. 4402-4407, 1998.

340 Resnick LM, “Cellular ions in hypertension, insulin resistance, obesity, and diabetes: unifying theme.” J Am Soc Nephrol, vol. 3, s ppl. 4, pp. 578-585, 1992.

341 Karppanen H, Neuvonen PJ, “Ischaemic heart-disease and soil magnesium in Finland: water hardness and magnesium in heart muscle. Lancet, Dec. 15, 1973.

342 Resnick LM, “Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of Syndrome X.” Am J Hypertens, vol. 6, no. 5, pt. 1, pp. 413-417, 1993.

343 Resnick LM, “The cellular ionic basis of hypertension and allied clinical conditions.” Prog Cardiovasc Dis, vol. 42, pp. 1-22, 1999.

344 Resnick LM et al., “Hypertension and peripheral insulin resistance. Possible Mediating role of intracellular free magnesium.” Am J Hypertens, vol. 3, no. 5, pt. 1, pp. 373-379, 1990.

345 HeK, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, Jacobs DR, Savage PJ, “Magnesium intake and incidence of metabolic syndrome among young adults.” Circulation, vol. 113, no. 13, pp. 1675-1682, 2006.

346 Paolisso G et al., “Low fasting and insulin-mediated intracellular magnesium accumulation ii1 hypertensive patients with left ventricular hypertrophy; role of insulin resistance.” Hypertension, vol. 9, pp. 199-203, 1995.

347 Nadler JL et al., “Magnesium deficiency produces insulin resistance and 1Ilcreased thromboxane synthesis.”, Hypertension, vol. 21, no. 6, pt. 2, pp. 1024- 1029, 1993.

348 Chacko SA et al., “Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randon1ized, double-blind, controlled, crossover trial in overweight individuals.,” Am J Clin Nutr, vol. 93, no. 2, pp. 463-473, 2011.

349 Bardicef M et al., “Extracellular and intracellular magnesium depletion in pregnancy and gestational diabetes.” Am J Obstet Gynecol, vol. 172, no. 3, pp. 1009-1013, 1995.

350 Resnick LM et al., “Intracellular and extracellular magnesium depletion in type 2 (non-insulin-dependent) diabetes mellitus.” Diabetologia, vol. 36, no. 8, pp. 767-770, 1993.

351 Chrysant SG, Chrysant GS. “Usefulness of the poly-pill for the prevention of cardiovascular disease and hypertension.” Curr Hypertens Rep, vol. 18, no. 2, p. 14, 2016.

352 Gommers LM et al., “Hypomagnesemia in type 2 diabetes: a vicious circle?” Diabetes, vol. 65, no. 1, pp. 3-13, 2016.

353 Kao WH et al., “Serum and dietary mag:t1esium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study.” Arch Intern Med, vol. 159, no. 18, pp. 2151-2159, 1999.

354 Lima M de L, “The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes.” Diabetes Care, vol. 83, no. 5, pp. 682-686, 1998.

355 Paolisso G, Barbagallo M, “Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium.” Am J Hypertens, vol. 10, no. 3, pp. 346-355, 1997.

356 Kim DJ et al., “Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes.” Diabetes Care, vol. 33, pp. 2604–2610, 2010.

357 Yokota K et al., “Clinical efficacy of magnesium supplementation in patients with type 2.” J Am Coll Nutr, vol. 23, no. 5, pp. 506S-509S, 2004.

358 Kishimoto Y et al., “Effects of magnesium on postprandial serum lipid responses in healthy human subjects.” Br J Nutr; vol. 103, pp. 469-472, 2010.

359 Mooren FC et al., “Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects-a double-blind, placebo-controlled, randomized trial.” Diabetes Obes Metab, vol. 13, no. 3, pp. 281-284, 2011.

360 Guerrero-Romero F, Rodriguez-Moral M, “Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial.” Eur J Clin Invest, vol. 41, no. 4, pp. 405- 410, 2011

361 Lu J et al., “Serum mag:t1esium concentration is inversely associated with albuminuria and retinopathy among patients with diabetes.” J Diabetes Res, 1260141, 2016.

362 Veronese N et al., “Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials.” Eur J Clin Nutr, doi: 10.1038/ejcn.2016.154. [Epub ahead of print]

363 Bherwani S et al., “Hypomagnesaemia: a modifiable risk factor of diabetic nephropathy.” Horm Mol Biol Clin lnvestig, 2016, doi: 10.1515/ hmbci-2016-0024. [Epub ahead of print]

364 Barbagallo M, Dominguez LJ, “Magnesium and type 2 diabetes.” World J Diabetes, vol. 6, no. 10, pp. 1152-1157, 2015.

365 Guerrero-Romero F et al., “Oral magnesium supplementation improves glycemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial.” Diabetes Metab, vol. 41, no. 3, pp. 202-207, 2015.

366 Dabelea D et al., “Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009.” JAMA, vol. 311, no. I 7, pp. 1778-1786, 2014.

367 Huerta MG et al., “Magnesium deficiency is associated, with insulin resistance in obese children.” Diabetes Care, vol. 28, no. 5, pp. 1175-1181, 2005.

368 Merz CN et al., “Oral magnesium supplementation inhibits platelet­ dependent thrombosis in patients with corona1-yarte1-ydisease.” Am J Cardiol, vol. 84, pp. 152-156, 1999.

369 Lima M de L, “The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes.” Diabetes Care, vol. 83, no. 5, pp. 682-686, 1998.

370 Engelen W, Bouten A, De Leeuw I, De Block C, “Are low magnesium levels in type 1 diabetes associated with electromyographical sig:t1s of polyneuropathy?” Magnes Res, vol. 13, no. 3, pp. 197-203, 2000.

371 Djurhuus MS et al., “Effect of moderate improvement in metabolic control on magnesium and lipid concentrations magnesium patients with type 1 diabetes.” Diabetes Care, vol. 22, no. 4, pp. 546-554, l 999.

372 Squires S, “The amazing statistics and dangers of soda pop.” Washington Post, February 27, 2001.

373 Ludwig DS et al., “Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis.” Lancet, vol. 357, no. 9255, pp. 505-508, 2001.

374 Bellisle F, Rolland-Cachera MF, “How sugar-containing drinks might increase adiposity in children.” Lancet, vol. 357, no. 9255, pp. 490-491, 2001.

375 Malik VS et al., “Sugar-sweetened beverages and weight gain in children and adults: a systematic review and meta-analysis.” Am J Clin Nutr, vol. 98, no. 4, pp. 1084-1102, 2013.

376 Bernstein J et al., “Depression of lyn1phocyte transformation following oral glucose ingestion.” Am J Clin Nutr, vol. 30, p.613, 1977.

377 Sanchez A et al., “Role of sugars m human neutrophilic phagocytosis.” Am J Clin Nutr, vol. 26, no. 11, pp. 1180-1184, 1973.

378 Kijak E et al., “Relationship of blood sugar level and leukocytic phagocytosis.” S Calif State Dent Assoc J, vol. 32, no. 9, l964.

379 Campbell-McBride N, Gut and Psychology Syndrome. Medinform, Cambridge, UK, 2010.

380 Lima M de L, “The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes.” Diabetes Care, vol. 83, no. 5, pp.682-686, 1998.

381 Yang CY et al., “Magnesium in drinking water and the risk of death from diabetes mellitus.” Magnes Res, vol. 12, no. 2, pp. 131-137, 1999.

382 Zhao HX et al., “Drinking water composition and childhood-onset type 1 diabetes mellitus in Devon and Cornwall, England.” Diabet Med, vol. 18, no. 9, pp. 709-717, 2001.

383 Howard MH, “Magnesium deficiency in peripheral vascular disease.” J Nutritional Med, vol. 1, p. 39, I 990.

384 Werbach M, “Premenstrual syndrome: magnesium.” Townsend Letter for Doctors, June 1995, p. 26.

385 Sherwood RA et al., “Magnesium and the premenstrual syndrome.” Ann Clin Biochem, vol. 23, no. 6, pp. 667-670, 1986.

386 Posaci C et al., “Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome.” Acta Obstet Gynecol Scand, vol. 73, no. 6, pp.452-455, 1994.

387 Facchinetti F et al., “Oral magnesium successfully relieves premenstrual mood changes.” Obstet Gynecol, vol. 78, no. 2, pp. 177-181, 1991

388 Somer E, The Essential Guide to Vitamins and Minerals. HarperCollins, New York, 1995.

389 Murray M, Encyclopedia of Natural Medicine, 2nd ed. Prima, Rocklin, CA, 1998.

390 Muneyvirci-Delale O et al., “Sex steroid hormones modulate serum ionized magnesium and calcium levels throughout the menstrual cycle in women.” Fertil Steril, vol. 69, no. 5, pp. 58-62, 1998.

391 Li W et al., “Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence.” Brain Res Bull, vol. 54, no. 1, pp. 83-89,2001.

392 Marz R, Medical Nutrition from Marz，2nd ed. Omni Press, Portland, OR, 1997.

393 Benassi L et al., “Effectiveness of magnesium pidolate in the prophylactic treatment of primary dysmenorrhea.” Clin Exp Obstet Gynecol, vol.19, no. 3, pp.176-179, 1992.

394 Fontana-Klaiber H, Hogg B, “Therapeutic effects of magnesium in dysmenorrhea. “Schweiz Rundsch Med Prax, vol. 79, no. 16, pp.491-494, 1990.

395 Seifert B et al., “Magnesium-a new therapeutic alternative in primary dysmenorrhea. ”Zentralbl Gynakol, vol. 111, no. 11, pp. 755-760, 1989.

396 Muneyvirci-Delale O et al., “Divalent cations in women with PCOS:Implications for cardiovascular disease.” Gynecol Endoclinol, vol. 15, no. 3, pp. 198-201, 2001.

397 Goldberg B, Alternative Medicine Guide: Women’s Health Series 1. Future Medicine, Tiburon, CA, 1998.

398 Franz KB, “Magnesium intake during pregnancy. “Magnesium, vol. 6, pp. 18-27, 1987.

399 Dalton LM et al., “Magnesium in pregnancy.” Nutr Rev, vol. 74, no. 9, pp. 549-557, 2016.

400 Edorh AP, Tachev K, Hadou T, Gbeassor M, Sanni A, Creppy EE, Le Faou A, Rihn BH, “Magnesium content in seminal fluid as an indicator of chronic prostatitis.” Cell Mol Biol, vol. 49, pp. 419-423, 2003.

401 Jafrin W et al., “An evaluation of serum magnesium status in preeclampsia compared to the normal pregnancy.” Mymensingh Medicine J, vol. 23, no. 4, pp. 649-653, 2014.

402 Conradt A, Weidinger AH, “The central position of magnesium in the management of fetal hypotrophy-a contribution to the pathomechanism of utero-placental insufficiency, prematurity and poor intrauterine fetal growth as well as pre-eclampsia.” Magnesium Bull, 124, 1982.

403 Handwerker SM et al., “Ionized serum magnesium levels in umbilical cord blood of normal pregnant women at delivery: relationship to calcium, demographics, and birthweight.” Am J Pe1inatol, vol. 10, o. 5, pp. 392-397, 1993.

404 Handwerker SM, Altura BT, Altura BM, “Serum ionized magnesium and other electrolytes in the antenatal period of human pregnancy.” J Am Coll Nut1, vol. 15, no. 1, pp. 36-43, 1996.

405 Almonte RA et al., “Gestational magnesium deficiency is deleterious to fetal outcome. ” Biol Neonate, vol. 76, no. 1, pp. 26-32, 1999.

406 Seelig MS, “Toxemias of pregnancy, postpartum cardiomyopathy and SIDS in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications: a review.” J Am Coll Nutr, vol. 13, no. 5, pp. 429-446, 1994.

407 Lazard EM, “A preliminary report on the intravenous use of magnesium sulphate in puerperal eclampsia.” Am J Obst Gynec, vol. 9, pp. 178 188, 1925.

408 Seelig MS, Magnesium Deficiency in the Pathogenesis of Disease: Early Roots of Cardiovascular, Skeletal, and Renal Abnormalities. Plenum, New York, 1980.

409 Seelig MS, “Prenatal and neonatal mineral deficiencies: magnesium, zinc and chromium.” In Clinical Disorders in Pediatric Nutrition, Marcel Dekker, New York, pp. 167-196, 1982.

410 Seelig MS, “Magnesium in pregnancy: special needs for the adolescent mother.” J Am Coll Nutr, vol. 10, p. 566, 1991.

411 Caddell JL, “Magnesium deficiency promotes muscle weakness, contributing to the risk of sudden infant death (SIDS) in infants sleeping prone.” Magnes Res, vol. 14, nos. 1-2, pp. 39-50, 2001.

412 Caddell JL, “A triple-risk model for the sudden u1fant death syndrome (SIDS) and the apparent life-threatening episode (ALTE): the stressed magnesium deficient weanling rat.” Magnes Res, vol. 14, no. 3, pp. 227- 238, 2001.

413 Durlach J et al., “Magnesium and thermoregulation. I. Newborn and infant. Is sudden infant death syndrome a magnesium-dependent disease of the transition from chemical to physical thermoregulation?” Magnes Res, vol. 4, pp. 137-152, 1991.

414 Nelson KB et al., “Can magnesium sulfate reduce the risk of cerebral palsy in very low birth weight infants?” Pediatrics, vol. 95, no. 2, 1995.

415 Schendel D et al., “Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low birth-weight children aged 3-5 years. JAMA, vol. 276, pp. 1805-1810, 1996.

416 Declhia HV, Banks DE, “Pulmonary response to hyperoxia: effects of magnesium.” Envilon Health Perspect, vol. 1 02, suppl. 10, pp. l O1- 105, 1994.

417 Oorschot DE, “Cerebral palsy and experimental hypoxia-induced perinatal brain injury: is magnesium protective?” Magnes Res, vol. 13, no. 4. pp. 265-273, 2000.

418 Bara M, Guiet-Bara A, “Magnesium regulation of Ca2+ channels in smooth muscle and endothelial cells of human allantochorial placental vessels.” Magnes Res, vol. 14, nos. 1-2, pp. 11-18, 2001.

419 Brown S, Better Bones, Better Body. Keats, New Canaan, CT, 1996.

420 Thomas AJ et al., “Ca, Mg and P status of elderly inpatients: dietary intake, metabolic balance studies and biochemical status.” Br J Nutr, vol. 62, pp. 211-219, 1989.

421 Bunker VW, “Osteoporosis in the elderly,” Br J Biomed Sci, vol. 51, no. 3, pp. 228-240, 1994.

422 Morehouse-Grand K, Grand S. “Can vegans have healthy bones? A literature review,” Topics in Integrative Health Care, vol. 5, no. 4, ID 5.4003, 2014.

423 The National Institutes of Health Osteoporosis Prevention, Diagnosis, and Therapy Consensus Statement, Mar. 2000.

424 Zheng J et al., “Association between serum level of magnesium and postmenopausal osteoporosis: a meta-analysis.” Biol Trace Elem Res, vol. 159, nos. 1-3, pp. 8-14, 2014.

425 Belluci MM et al., “Magnesium deficiency results in an increased formation of osteoclasts.” J Nutr Biodchem, vol. 24, no. 8, pp. 1488-1498, 2013.

426 Rude RK, “Magnesium deficiency-induced osteoporosis in the rat: uncoupling of bone formation and bone resorption.” Magnes Res, vol. 12, no. 4, pp. 257-267, 1999.

427 Rude RK et al., “Magnesium deficiency induces bone loss in the rat.” Miner Electrolyte Metab, vol. 24, no. 5, pp. 314-320, 1998.

428 Brodowski J, “Levels of ionized magnesium in women with various stages of postmenopausal osteoporosis progression evaluated on the basis of densitometric examinations.” Przegl Lek, vol. 57, no. 12, pp. 714- 716,2000.

429 Sojka JE, Weaver CM, “Magnesium supplementation and osteoporosis.”Nutr Rev, vol. 53, p. 71, 1995.

430 Goldberg B, Alternative Medicine Guide: Women’s Health Series 2. Future Medicine, Tiburon, CA, 1998.

431 Abraham GE, Grewal HA, “Total dietary program emphasizing magnesium instead of calcium: effect on the mineral density of calcaneous bone in postmenopausal women on hormonal therapy.” J Reprod Med, vol. 35, no. 5, pp. 503-507, 1990.

432 Seelig MS, “Increased magnesium need with use of combined estrogen and calcium for osteoporosis.” Magnes Res, vol. 3, pp. 197-215, 1990.

433 Goldberg B, Alternative Medicine Guide: Women’s Health Series 2. Future Medicine, Tiburon, CA, 1998.

434 Brown S, Better Bones, Better Body. Keats, New Canaan, CT, 1996.

435 Compston J et al., “Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.” Maturitas, vol. 75, no. 4, 392-396, 2013.

436 Maggio M et al., “Magnesium and anabolic hormones in older men.” Int J Androl, vol. 34, no. 6, part 2, pp. e594-e600, 2011.

437 Cinar V et al., “Effects of magnesium supplementation on testosterone levels of athletes and sedentary subjects at rest and after exhaustion.” Biol Trace Elem Res, vol. 140, no. 1, pp. 18-23, 2011.

438 Rotter I et al., “Relationship between serum magnesium concentration and metabolic and hormonal disorders in middle-aged and older men.” Magnes Res, vol. 28., no. 3, pp. 99-107, 2015.

439 Stafford RS et al., “National trends in osteoporosis visits and osteoporosis treatment, 1988-2003.” Arch Intern Med, vol. 164, pp. 1525-1530, 2004.

440 Abrams SA et al., “Magnesium metabolism in 4-year-old to 8-year-old children.” J Bone Miner Res, vol. 29, no, 1, pp. 118-122, 2014.

441 Tucker KL et al., “Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women.” Am J Clin Nutr, vol. 69, no. 4, pp. 727-736, 1999.

442 Curfman G, “FDA strengthens warning that NSAIDs increase heart attack and stroke risk.” Harvard Health Blog, July 13, 2015, www.patienteducationcenter.org/fda-strengthens-warning-that-nsaids-increase-heart-attack-and-stroke-risk-3.

443 Schmidt Met al., “Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control stt1dy,” BMJ, vol. 343, d3450, 2011.

444 Li Y, Yue J, Yang C. “Unraveling the role of Mg++ m osteoarthritis.” Life Sci, vol. 147, pp. 24-29, 2016.

445 Zeng C et al., “Relationship between serum magi1esium concentration and radiographic knee osteoarthritis.” J Rheumatol, vol. 42, no. 7, pp. 1231-1236, 2015.

446 Hall WD et al., “Risk factors for kidney stones in older women in the southern United States.” Am J Med Sci, vol. 322, no. l, pp. 12-18, 2001.

447 http://lowoxalateinfo.com/ guide-to-low-oxalate-greens.

448 Milne DB, Nielsen FH, “The interaction between dietary fructose and magnesium adversely affects macromineral homeostasis in men.” J Am Coll Nutr, vol. 19, no. 1, pp. 31-37, 2000.

449 Institute of Medicine, Dietary Reference Intake for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluo1ide. National Academy Press, Washington DC, 1997.

450 Milne D, Nielsen F, “Too much soda may take some fizz out of the bones.” Proc ND Acad Sci, vol. 51, p. 212, 1998.

451 Bunce GE et al., “Distribution of calcium and magnesium in rat kidney homogenate fractions accompanying magnesium deficiency induced nephrocalcinosis.” Exp Mol Pathol, vol. 21, no. I, pp. 16-28, 1974.

452 ohansson Get al., “Effects of magnesium hydroxide in renal stone disease.” J Am Coll Nutr, vol. l, no. 2, 1982.

453 Prien EL, “Magnesium oxide-pyridoxine therapy for recurring calcium oxalate urinary calculi.” J Urology, vol. 112, pp. 509-551, 1974.

454 Johannson G et al., “Biochemical and clinical effects of prophylactic treatment of renal calcium stones with magnesium hydroxide.” J Urol, vol. 124, pp. 770-774, 1980.

455 Driessens FC, Verbeeck RM, “On the prevention and treatment of calcification disorders of old age.” Med Hypotheses, vol. 3, pp. 131-137, 1988.

456 Labeeuw Met al., “Role of magnesium in the physiopathology and treatment of calcium renal litl1iasis.” Presse A1ed, vol. 16, no. l, pp. 25- 27, 1987.

457 Massey L, “Magnesium therapy for nephrolithiasis.” Magnes Res, vol. 18,no. 12, pp. 123-126, 2005.

458 Jeppesen BB, “Greenland, a soft-water area with a low incidence of ischemic heart death.” A1agnesiwn, vol. 6, no. 6, pp. 307-313, 1987.

459 Loh AH, Cohen AH. “Drug-induced kidney disease—pathology and current concepts.” Ann Acad Med Singapore, vol. 38, no. 3, pp. 240-250, 2009.

460 www.empowher.com/kidney-failure/content/top-ten-drugs-cause-kidney-damage.

461 Xie Yet al., “Proton pump inhibitors and risk of incident CKD and progression to ESRD.” J Am Soc Nephrol, vol. 27, no. 10, pp. 3153-3163, 2016.

462 Thongprayoon C et al., “High mortality risk m chronic kidney disease and encl stage kidney disease patients with clostridium difficile infection: 5ysternatic review and meta-analysis.” J Nature Sci, vol. I, no. 4, p. e85, 2015.

463 Geiger H, Wanner C. “Magnesium in disease.” Clin Kidney J, vol. 5, suppl. 1, pp. i25-i38, 2012.

464 Jahnen Dechent W, Ketteler M. “Magnesium basics.” Clin Kidney J, vol. 5, suppl. 1, pp. i3-i14, 2012.

465“Magnesium-a versatile and often overlooked element: New perspectives with a focus on chronic kidney disease.” Clin Kidney J, vol. 5, suppl. 1, 2012.

466 Alhosaini Met al., “Magnesium and dialysis: the neglected cation.” Am J Kidney Dis, vol. 66, no. 3, pp. 523-531, 2015.

467 Markell MS, Altura BT, et al. “Deficiency of serum ionized magnesium in patients receiving hemodialysis or peritoneal dialysis.” ASAIO J, vol. 39, no. 3, pp. M801-M804, 1993.

468 Alhosaini M et al., “Magnesium and dialysis: the neglected cation.” Am J Kidney Dis, vol. 66, no. 3, pp. 523-531, 2015.

469 Demer LL, Tii1tut Y “Vascular calcification: pathobiology of a multifaceted disease.” Circulation, vol. 117, no. 22, pp. 2938-2948, 2008.

470 McCarty MF, Dinicolantonio JJ, “The molecular biology and pathophysiology of vascular calcification.” Postgrad Med, vol. 126, no: 2, pp. 54-64, 2014.

471 www.mgwater.com/ cancer.shtml.

472 www.mgwater.com/ rodtitle.shtml.

473 Daniel D et al., “Magnesium intake and incidence of pancreatic cancer: the Vitamins and Lifestyle Study.” Br J Cancer, vol. 113, no. 11, pp. 1615-1621, 2015.

474 Ma E et al., “High dietary intake of magnesium may decrease risk of colorectal cancer in Japanese men.” J Null; vol. 140, pp. 779-785, 2010.

475 Kuno T et al., “Organomagnesium suppresses inflammation-associated colon carcinogenesis in male Crj: CD-1 mice.” Carcinogenesis vol. 34, no. 2, pp. 361-369, 2013.

476 Tao MH et al., “Associations of intakes of magnesium and calcium and survival among women with breast cancer: results from Western New York Exposures and Breast Cancer (WEB) Study.” Am J Cancer Res, vol. 6, no. I, pp. 105-113, 2015.

477 Piovesan D et al., “The human ‘magnesome’: detecting magnesium binding sites on human proteii1s.” BMC Bioinformatics, vol. 13, suppl. 14, p. S10, 2012.

478 www.mgwater.com/ rodtitle.shtml.

479 Goldstein JA, ed., Chronic Fatigue Syndromes: The Limbic Hypothesis. Haworth Press, New York, 1993.

480 Seelig MS, “Review and hypothesis: might patients with the chronic fatigue syndrome have latent tetany of magnesium deficiency.” J Chron Fatigue Syndl, vol. 4, pp. 77-108, 1998.

481 Papadopol V, Tuchenclria E, Palamaru I, “Magnesium and some psychological features in two groups of pupils (magnesium and psychic features).” Magnes Res, vol. 14, nos. 1-2, pp. 27-32, 2001.

482 Durlach V et al., “Neurotic, neuromuscular and autonomic nervous form of magnesium imbalance.” Magnes Res, vol. 10, pp. I69-195, 1997.

483 Cox IM, “Red blood cell magnesium and chronic fatigue syndrome.” Lancet, vol. 337, pp. 757-760, 1991.

484 Goldberg B, Chronic Fatigue. Fibromyalgia and Environmental Illness: 26 Doctors Show You How They Reverse These Conditions with Clinically Proven Alternative Therapies. Future Medicine, Tiburon, CA, 1998.

485 Seelig MS, “Athletic stress, performance and magnesium in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic in1plications: a review.” J Am Coll Nutr, vol. 13, no. 5, pp. 429-446, 1994.

486 Abraham GE, Flechas JD, “Management of fibromyalgia: rationale for the use of magnesium and malic acid.” P J Nutr Med, vol. 3, pp. 49-59, 1992.

487 Rogers S. Detoxify or Die. Sand Key, Sarasota, FL, 2002.

488 “CDC releases most extensive assessment to date of Americans’ exposure to environmental chemicals,” Centers for Disease Control and Prevention telebriefing, January 31, 2003, www.cdc.gov/media/ transcripts/t030131.htm.

489 “GAO finds that USDA, EPA have neglected pledge to cut pesticide use,” U.S. General Accounting Office, U.S. Newswire, Sept. 27, 2001, http://leahy.senate.gov/press/200109/010927.html.

490 www.cdc.gov/exposurereport.

491 www.texascemer.org/almanac/Waste/MUNICIPALCH8P2.HTML.

492 Kreutzer R et al., “Prevalence of people reporting sensitivities to chemicals in a population-based survey.” Am J Epidemiol, vol. 150, no. 1, pp. 1-12, 1999.

493 “Everyday carcinogens: stopping cancer before it starts.” Workshop on Primary Cancer Prevention, McMaster University, Hamilton, Ontario, Canada, March 26-27, 1999.

494 Goering PL et al., “Toxicity assessment of mercury vapor from dental amalgams.” Fundam Appl Toxicol, vol. 19, no. 3, pp. 319-329, 1992.

495 Halbach S, “Amalgam tooth fillings and man’s mercury burden. Review.” Hum Exp Toxicol., vol. 13, no. 7, pp. 496-50 I, 1994.

496 Lorscheider FL et al., “Mercury exposure from ‘silver’ tooth fillings: emerging evidence questions a traditional dental paradigm.” FASEB J, vol. 9, no. 7, pp. 504–508, 1995.

497 Arenholt-Bindslev D, Larsen AH, “Mercury levels and discharge in waste water from dental clinics.” Water Air Soil Pollut, vol. 86, nos. 1-4, pp.93-99, 1996.

498 Drasch G et al., “Comparison of the body burden of the population of Leipzig and Munich with the heavy metals cadmium, lead and mercury—a study of human organ samples.” Gesundheitswesn, vol. 56, no. 5, pp. 263-267, 1994.

499 Liu XY, Jin TY, Nordberg GF, “Increased urinary calcium and magnesium excretion in rats injected, with mercuric chloride.” Pharmacol Toxicol, vol. 68, no. 4, pp. 254–259, 1991.

500 Durlach J, “Diverse applications of mag11esium therapy.” In Handbook of Metal-Ligand Interactions in Biological Fluids—Bioinorganic Medicine, vol. 2, Marcel Dekker, New York, 1995.

501 Kedryna T et al., “Effect of environmental fluorides on key biochemical processes in humans.” Folia Med Cracov, vol. 34, no. 1-4, pp. 49-57, 1993.

502 Semczuk M, Semczuk-Sikora A, “New data on toxic metal intoxication (Cd, Pb, and Hg in particular) and Mg status during pregnancy. Review.” Med Sci Monit, vol. 7, no. 2, pp. 332-340, 2001.

503 Durlach J et al., “Magnesium: a competitive inhibitor of lead and cadmium. Ultrastn1cture sti.1dies of the human amniotic epithelial cell.” Magnes Res, vol. 3, pp. 31-36, 1990.

504 Soldatovic D et al., “Contribution to interaction between magnesium and toxic metals: the effect of prolonged cadmium intoxication on magnesium metabolism in rabbits.” Magnes Res, vol. 11, no. 4, pp. 283-288, 1998.

505 Allen VG, “Influence of aluminum on magnesium metabolism.” In Altura BM, Durlach J, Seelig MS, eds., Magnesium in Cellular Processes and Medicine, Krager, Basel, 1987, pp. 50-66

506 Rogers S, The EI Syndrome: An Rx for Environmental Illness, rev. ed. Sand Key, Sarasota, FL, 1995.

507 Seelig M, “Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review).”J Am Coll Nutr, vol. 13, no. 5, pp. 429 446, 1994.

508 Phsicians’ Desk Reference, 56th ed., Medical Economics, Oradell, NJ, 2002.

509 Gurkan F et al., “Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy.” Eur J Emerg Medicine, vol. 6, no. 3, pp. 2?1-205, 1999.

510 Ciarallo L et al, “Intravenous magnesium therapy for moderate severe pediatric asthma: results of randomized, placebo-controlled trial.” J Pediatr, vol. 129, pp. 809-814, 1996.

511 Dominguez LJ et al, “Bronchial reactivity and intracellular magnesium: a possible mechanism for the bronchodilating effects of magnesium in as lm1a.” Clin Sci (Colch), vol. 95, no. 2, pp. 137-142, 1998.

512 Blitton J, “Dietary magnesium, lung function, wheezing and airway hyperreactivity in a random population sample.” Lancet, vol. 344, pp. 357-362, 1994.

513 Kew KM et al., “Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department.” Cochrane Database Syst Rev, vol. 5, CD010909, 2014.

514 Santi M et al., “Magnesium in cystic fibrosis: Systematic review of the literature.” Pediatr Pulmonol, vol. 51, no. 2, pp. 196-202, 2016.

515 Barbagallo M et al., “Cell1tlar ionic alterations with age: relation to hypertension and diabetes.” J Am Geriatr Soc, vol. 48, no. 9, pp.1111-1116, 2000.

516 Barbagallo M, “Diabetes mellitus, hypertension and ageing: the ionic hypothesis of ageing and cardiovascular- metabolic diseases.” Diabetes Metab, vol. 23, no. 4, pp. 281-294, 1997.

517 Hartwig A, “Role of magnesium in genomic stability.” Mutat Res, vol. 18, no. 475 (1-2), pp. 113-121, 2001.

518 Worwag M et al., “Prevalence of magnesium and zinc deficiencies in nursing home residents in Germany.” Magnes Res, vol. 12, no. 3, pp.181-189, 1999.

519 Paolisso G et al., “Mean arterial blood pressure and serum levels of the molar ratio of insulin-like growth factor-1 to its binding protein-3 in centenarians.” J Hypertens, vol. 17, pp. 67-73, 1999.

520 Durlach J et al., “Magnesium and ageing. Ⅱ. Clinical data: aetiological mechanisms and pathophysiological consequences of magnesium deficit in the elderly.” Magnes Res, vol. 6, no. 4, pp. 379-394, 1993.

521 Leone N et al., “Zinc, copper and magnesium and risks for all-cause, cancel; and cardiovascular mortality.” Epidemiology, vol. 17, no. 3, pp. 308-314, 2006.

522 Guasch-Ferre M et al., “Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk.” J Nutr, vol. 14-1-, no. 1, pp. 55-60, 2014-.

523 Wolf F, Hilewitz A. Hypomagnesaemia in patients hospitalised in internal medicine is associated with increased mortality. Int J Clin Pract, vol. 68, no. 1, pp. 111-116, 2014.

524 Li W et al., “Antioxidants prevent elevation in [Ca(2+)](i) induced by low extracellular magnesium in cultured canine cerebral vascular smooth muscle cells: possible relationship to Mg(2+) deficiency-induced vasospasm and stroke.” Brain Res Bull, vol. 52, no. 2, pp. 151-154, 2000

525 Harnwig A, “Role of magnesium in genomic stability.” Mutat Res, vol. 18, no. 475 (1-2), pp. 113-121, 2001.

526 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Sante Fe, NM, 1997.

527 Wolf FI, Trapani V, et al., “Magnesium deficiency affects mammary epithelial cell proliferation: involvement of oxidative stress.” Nrutr Cancer, vol. 61, no. 1, pp. 131-136, 2009.

528 Wolf FI et al., “TRPM7 and magnesium, metabolism, mitosis: An old path with new pebbles.” Cell Cycle, vol. 9, no. 17, p. 3399, 2010.

529 Laires MJ et al., “Role of cellular magnesium in health and human disease.” Front Biosci, vol. 1, no. 9, pp. 262-276, 2004.

530 Giovanni G et al., “Molecular mechanism of endothelial and vascular aging implications for cardiovascular disease.” Eur Heart J, vol. 36, no. 48, pp. 3392-34-03, 2015.

531 Liu G, Slutsky I, “Magnesium may reverse middle-age memory loss.” MIT Tech Talk, vol. 49, no. 12, December 8, 2004.

532 Abumaria N et al., “Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala.” J Neurosci, vol. 31, no. 42, pp. 14871-14881, 2011.

533 Shah NC et al., “Short-term magnesium deficiency downregulates telomerase, upregulates neutral sphingomyelinase and induces oxidative DNA damage in cardiovascular tissues: relevance to atherogenesis, cardiovascular diseases and aging.” Int J Clin Exp Med, vol. 7, no. 3, pp. 497-514, 2014.

534 Rowe WJ, “Correcting magnesium deficiency may prolong life.” Clin Inlerv Aging, vol. 7, pp. 51-54, 2012.

535 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Sante Fe, NM, 1997.

536 Rondeau V et al., “Aluminum in drinking water and cognitive decline in elderly subjects: the Paquid cohort.” Am J E, Epidemiol, vol. 154, no. 3, pp. 288-290, 2001.

537 Rondeau V et al., “Relation between aluminum concentrations m drinking water and Alzheimer’s disease: an 8-year follow-up study.” Am J Epidemiol, vol. 152, pp. 59-66, 2000.

538 Durlach J. “Magnesium depletion and pathogenesis of Alzheimer’s disease.” Magnes Res, vol. 3, no. 3, pp. 217-218, 1990.

539 Foster HD, “How aluminum causes Alzheimer’s disease: the implications for prevention and treatment of Foster’s multiple antagonist hypothesis.” J Ortho Mol Med, vol. 15, 2000.www.orthomolecular.org/library/jom/2000/articles/ 2000-v15n01-p021.shtml.

540 Andrasi E et al., “Disturbances of magnesium concentrations in various brain areas in Alzheimer’s disease.” Magnes Res, vol. 13, no. 3, pp. 189-196, 2000.

541 Durlach J, “Diverse applications of magnesium therapy.” In Handbook of Metal-Ligand Interactions in Biological Fluids—Bioinorganic Medicine, vol. 2, Marcel Dekker New York, 1995.

542 Barbagallo M et al., “Altered ionized magnesium levels in mild-to-moderate Alzheimer’s disease.” Magnes Res, vol. 24, no. 3, pp. SJ15-8121, 2011.

543 Cherbuin N et al., “Dietary mineral intake and risk of mild cognitive impairment: the PATH Through Life Project.” Front Aging Neurosci, vol. 6, no. 4, p. 4, 2014.

544 Andrasi E, Igaz S, Molnàr Z, Mako S, “Disturbances of magnesium concentrations in various brain areas in Alzheimer’s disease.” Mgnes Res, vol. 13, pp. 189-196, 2000.

545 Xu ZP et al., “Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer’s model.” PLoS One, vol. 9, no. 9, p. el08645, 2014.

546 Li W et al., “Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model.” Mol Brain, vol. 7, 65, 2014.

547 de Baaij JHF et al., “Magnesium in man: implications for health and disease.” Physiol Rev, vol. 95, no. 1, pp. 1-46, 2015.

548 Yasui M et al., “Calcium, magnesium and aluminum concentrations in Parkinson’s disease.” Neurotoxicology, vol. 13, no. 3, pp. 593-600, 1992.

549 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Sante Fe, NM, 1997.

550 Nelson L, “Pesticides and Parkinson’s disease.” American Academy of Neurology 52nd Annual Meeting, San Diego, CA, April 29-May 6, 2000.

551 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Sante Fe, NM, 1997.

552 www.psychologytoday.com/basics/dopamine.

553 Blaylock RL, Excitotoxins: The Taste That Kills. Health Press, Sante Fe, NM, 1997.

554 Altura BM, Altura BT, “Role of magnesium in patho-physiological processes and the clinical utility of magnesium ion selective electrodes.” Scand J Clin Lab Invest Suppl，vol. 224, pp.211-234, 1996.

555 Altura BT, Altura BM, “A method for distinguishing ionized, complexed and protein-bound Mg in normal and diseased subjects.” Scand J Clin Lab Invest Suppl, vol. 217, pp. 83-87, 1994.

556 Altura BT et aI., “Comparative findings on serum IMg2+ of normal and diseased human subjects with the NOVA and KONE ISE’s for Mg2+.” Scand J Clin Lab Invest Suppl, vol. 217, pp. 77-81, 1994.

557 Altura BT et al., “Characterization of a new ion selective elctrode for ionized magnesium in whole blood, plasma, serum, and aqueous samples.” Scand J Clin Lab Invest Suppl, vol. 217, pp. 21-36, 1994.

558 Altura BT et al., “A new method for the rapid determination of ionized Mg2 in whole blood, serum and plasma.” Methods and Findings in Exp Clin Pharmacol, vol. 4, pp. 297-304, 1992.

559 Altura BT, Altura BM, “Measurement of ionized magnesium in whole blood, plasma and serum wvith a new ion-selective electrode in healthy and diseased human subjects.” Magnes Trace Elem, vol. 10, nos. 2-4, pp. 90-98, 1991-1992.

560 Altura BT, Altura BM, “A method for distinguishing ionized, complexed and protein-bound Mg in normal and diseased subjects.” Scand J Clin Lab Invest Suppl, vol. 217, pp. 83-87, 1994.

561 Altura BM, Altura BT, “Role of magnesium in patho-physiological processes and the clinical utility of magnesium ion selective electrodes.” Scand J Clin Lab Invest Suppl, vol. 224, pp. 211-234, 1996.

562 Altura BT et al., “Clinical studies with the NOVA ISE for IMg2+.” Scand J Clin Lab Invest Suppl, vol. 217, pp. 53-67, 1994.

563 Marcus JC, Altura BT, Altura BM, “Serum ionized magnesium in post­traumatic headaches.” J Pediatr, vol. 139, no. 3, pp. 459-462, 2001.

564 Muneyvirci-Delale O et al., “Divalent cations women with PCOS: implications for cardiovascular disease.” Gynecol Endocrinol, vol. 3, pp. 198-201, 2001.

565 Marcus JC et al., “Serum ionized magnesium in premature and term infants.” Pediatr Neurol, vol. 4, pp. 311-314, 1998.

566 Scott VL et al., “Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation: a complication of citrate intoxication.” Liver Transpl Surg, vol. 2, no. 5, pp. 343-347, 1996.

567 Altura BT et al., “Low levels of serum ionized magnesium are found in patients early after stroke which result in rapid elevation in cytosolic free calcium and spasm in cerebral vascular muscle cells.” Neurosci Lett, vol. 230, no. 1, pp. 37-40, 1997.

568 Handwerker SM, Altura BT, Altura BM, “Serum ionized magnesium and other electrolytes in the antenatal period of human pregnancy.” J Am Coll Nutr, vol. 15, no. 1, pp. 36-43, 1996.

569 Memon ZI et al., “Predictive value of serum ionized but not total magnesium levels in head injuries.” Scand J Clin Lab Invest, vol. 55, no. 8, pp. 671-677, 1995.

570 Handwerker SM, Altura BT, Altura BM, “Ionized serum magnesium and potassium levels in pregnant women with preeclampsia and eclampsia.” J Reprot Medicine, vol. 40, no. 3, pp. 201-208, 1995.

571 Ismail Y et al., “The underestimated problem of using serum magnesium measurements to exclude magnesium deficiency in adults: a health warning is needed for ‘normal’ results.” Clin Chem Laboratory, vol. 48, no. 3, pp.323-327, 2010.

572 Mircetic RN, Dodig S, Raos M, Petres B, Cepelak I, “Magnesium concentration in plasma, leukocytes and urine of children with intermittent asthma.” Clin Chim Acta, vol. 312, nos. 1-2, pp. 197-203, 2001.

573 www.spectracell.com/clinicians/products/mnt.

574 www.exatest.com.

575 Ryzen E et al., “Parenteral magnesium tolerance testing in the evaluation of magnesium deficiency.” Magnesium, vol. 4, pp. 137-147, 1985.

576 Seelig MS, “The requirement of magnesium by the normal adult.” Am J Clin Nutr, vol. 14, pp. 342-390, 1964.

577 Seelig MS, “Magnesium requirements in human nutrition.” Magnes Bull, vol. 3, no. 1A, pp. 26-47, 1981.

578 Franz KB, “Magnesium intake during pregnancy.” Magnesium, vol. 6, pp. 18-27, 1987.

579 Seelig MS, “The requirement of magnesium by the normal adult.” Am J ClinNutr, vol. 14, pp. 342-390, 1964.

580 Seelig MS, “Magnesium requirements in human nutrition.” Magnes Bull, vol. 3, no. 1A, pp. 26-47, 1981.

581 Glei Met al., “Magnesium content of foodstuffs and beverages and magnesium intake of adults in Germany.” Magnes Bull, vol. 17, pp. 22- 28, 1995.

582 Cashman KD et al., “Optimal nutrition: calcium, magnesium and phosphorus.” Proc Nutr Soc, vol. 58, pp. 477-487, 1999.

583 Durlach J, Bac P, Bara M, Guiet-Bara A, “Cardiovasoprotective foods and nutrients: possible importance of magnesium intake.” Magnes Res, vol. 12, no. 1, pp. 57-61, 1999

584 Murray M, Encyclopedia of Nutritional Supplements. Prima, Rocklin, CA, 1996.

585 Wood M, Seven Herbs: Plants as Teachers. North Atlantic Books, Berkeley, CA, 1987.

586 Weed S, Healing Wise: The Wise Woman Herbal. Ash Tree Publishing, Woodstock, NY, 1989.

587 Duke JA, The Green Pharmacy. St. Martin’s Press, New York, 1998.

588 Chevallier A, The Encyclopedia of Medicinal Plants. DK Publishing, New York, 1996.

589 Jiang L et al., “Magnesium levels in drinking water and coronary heart disease mortality risk: a meta-analysis.” Nutrients, vol. 8, no. I, 2016.

590 Marx A et al., “Magnesium in drinking water and ischemic heart disease.” Epidemiol Rev, vol. 19, pp. 258-272, 1997.

591 Von Wiesenberger A, The Pocket Guide to Bottled Water. Contemporary Books, Chicago, 1991.

592 Laires MJ et al., “Role of cellular magnesium in health and human disease.” Front Biosci, vol. 9, pp. 262-276, 2004.

593 Durlach J, Magnesium in Clinical Practice. Libbey, London, 1988.

594 Fehlinger R, “Therapy with magnesium salts in neurological diseases.” Magnes Bull, vol. 12, pp. 35-42, 1990.

595 Ducroix T, “L’enfant spasmophile-Aspects diagnostiques et thérapeutiques.” Magnes Bull, vol. 1, pp. 9-15, 1984.

596 Seelig MS, “Athletic stress, performance and magnesium in consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications: a review.” J Am Coll Nutr, vol. 13, no. 5, pp. 429-446, 1994.

597 Slutsky I et al., “Enhancement of learning and memory by elevating brain magnesium.” Neuron, vol. 65, no. 2, pp. 165-177, 2010.

598 www.adelaide.edu.au/press/titles/magnesium.

599 Chazov EI, Malchikova LS, Lipina NV, Asafov GB, Smirnov VN, “Taurine and electrical activity of the heart.” Circ Res, vol. 35, suppl. 3, pp. 11-21, 1974.

600 Chahine R, Feng J, “Protective effects of taurine against reperfusion-induced arrhythn1ias in isolated ischemic rat heart.” Arznemittelforschung, vol. 48, no. 4·, pp. 360-364, 1998.

601 Johnson S, “The multifaceted and widespread pathology of magnesium deficiency,” Med Hypotheses, vol. 56, no. 2, pp. 163-170, 2001.

602 Rude RK et al., “Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency.” J Clin Endocrinol Metab, vol. 61, pp. 833-940, 1985.

603 Fuss M et al., “Correction of low circulating levels of 1,25-dihydroxy-vitamin D by 25-hydroxyvitamin D during reversal of hypomagnesaemia.” Clinical Endocrinol Oxf, vol. 31, pp. 31-38, 1989.

604 Manuel y Keenoy B, Moorkens G, Vertommen J, Noe M, Neve J, De Leeuw I, “Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium.” J Am Coll Nutr, vol. 19, no. 3, pp. 374-382, 2000.

605 Boericke OE, Pocket Manual of Homeopathic Materia Medica, 9th ed. Boericke & Runyon, Philadelphia, 1927.